Anti‑PD‑1 with lenalidomide and azacitidine for relapsed/refractory peripheral T‑cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single‑center Phase 2 interventional study gives a combination of an anti‑PD‑1 monoclonal antibody together with lenalidomide and azacitidine to adults with relapsed or refractory peripheral T‑cell lymphoma. Eligible participants must have measurable disease after prior therapies, be at least 18 years old, have ECOG performance status ≤2, and meet specified organ function requirements. Participants will receive the combination regimen and be followed for tumor response and safety outcomes. The trial is conducted at The First Affiliated Hospital of Soochow University in Suzhou, Jiangsu.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Pathological immunohistochemistry or flow cytometry confirmed that R/R PTCL with measurable (diameter greater than 1.5cm) lesions meets any of the following conditions: 1\> After 4 courses of standard first-line therapy or 2 courses of more than two-line therapy, the lesions were reduced by \<50%; 2\> PTCL with disease progression after first-line or induction therapy; 3\> After hematopoietic stem cell transplantation, new lesions appear or the size of previously affected lesions increased by more than 50%.
2. Age ≥ 18 years.
3. ECOG≤2分.
4. The main organ functions need to meet the following conditions:Hemogram needs to meet HB ≥70\*1012/L，PLT≥50\*109/L，NE≥1\*109/L；LVEF≥50%;CR≤132umol/l or CCr≥60 ml/min;ALT and AST≤2 times normal range；Lung function≤Level 1;dyspnea(CTCAE v5.0),and blood oxygen saturation without oxygen absorption\> 91%.
5. Subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study until the follow-up one year period of the study.
6. Estimated survival time ≥3 months.
7. Voluntary signing of informed consent.

Exclusion Criteria:

1. Accepted major surgery within 4 weeks before treatment.
2. Prior malignancy (other than Relapsed/Refractory Peripheral T-cell Lymphoma), except for cured malignant tumors with no active lesions for 3 years;Adequate treatment of inactive lesions in non-melanoma skin cancer,malignant tonsilloma or carcinoma in situ;
3. Patients who have previously received failed allogeneic hematopoietic stem cell transplantation.
4. Have stroke or intracranial hemorrhage within 3 months.
5. Evidence of complications or medical conditions, including but not limited, that may interfere the conduct of the study or place the patient at serious risk:significant cardiovascular disease(class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification、myocardial infarction within 6 months of screening、uncontrolled or symptomatic arrhythmias) and/or significant lung disease.
6. HIV infection and/or active hepatitis B or active hepatitis C.
7. Uncontrolled systemic infection.
8. Pregnant or breasting-feeding women.
9. According to the researchers' judgment, any life-threatening disease, medical condition or organ system dysfunction which can endanger the patient's safety and Interfer with the absorption or metabolism of anti-PD-1 monoclonal antibody plus Lenalidomide and Azacitidine,may put the results of a study at unnecessary risk.

Where it's running

• The First Affiliated Hospital of Soochow University
  Suzhou, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Caixia Li, M.D
• Email: licaixia@suda.edu.cn
• Phone: +86 512 67781856

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• XNW5004 versus Chidamide for relapsed or refractory peripheral T-cell lymphoma

  This will test whether XNW5004 tablets work better than Chidamide for adults (18–70) whose peripheral T-cell lymphoma has returned or not responded to prior treatments.

  Recruiting Phase 3 Evopoint Biosciences Inc. · Beijing, Beijing Municipality · NCT06776952

• Evaluating SHR-0302 and SHR-2554 for treating relapsed peripheral T-cell lymphoma

  This study is testing a new combination of two drugs to see if they can help people with relapsed peripheral T-cell lymphoma feel better and improve their treatment options.

  Recruiting Phase 2 Fudan University · Shanghai · NCT06519526

• CD20 antibody to prevent early EBV activation after a first allogeneic stem cell transplant

  Researchers are testing whether a CD20 monoclonal antibody can prevent EBV activation in people aged 14 to 70 after their first allogeneic stem cell transplant.

  Recruiting Phase 2/3 The First Affiliated Hospital of Soochow University · Hefei, Anhui and 9 other locations · NCT07929974

• BEBT-908 treatment for MEF2D-rearranged B-ALL that has come back or isn’t controlled

  This study tests BEBT-908 given IV to see if it can help people aged 14–75 with MEF2D-rearranged B-cell precursor ALL who have relapsed, are refractory, or still have measurable disease after treatment.

  Recruiting Phase 1 The First Affiliated Hospital of Soochow University · Suzhou · NCT07854652

• CMV-specific T cells after CMV reactivation in adults after HSCT

  This study tests CMV-specific immune recovery in adults who have their first CMV reactivation after an allogeneic HSCT to see how CMV-specific T cells change over time.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07688759

• Venetoclax and Azacitidine Consolidation After Remission in Intermediate-Risk AML

  We’re testing if a venetoclax-plus-azacitidine consolidation approach works as well as standard high-dose chemotherapy for adults with intermediate-risk AML who have already achieved remission and are headed to stem cell transplant.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07672262

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.